drugset
drugset / Trial / NCT05124795

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

NCT05124795 ↗

Phase 1 Terminated 18 enrolled Immunic AG
Non-randomizedSequentialOpen-labelTreatment

Summary

Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).

Timeline

Start
2021-12-09
Primary completion
2023-05-31
Completion
2023-05-31

Outcome

Outcome not reported

Stopped: “Lack of Efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject IMU-935 Unknown — —

Indications

prostate carcinoma